Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5136-5145

  Sun, Nan ^a   Chen, Zhaoli ^a   Tan, Fengwei ^a   Zhang, Baihua ^a   Yao, Ran ^a   Zhou, Chengcheng ^a   Li, Jiagen ^a   Gao, Yibo ^a   Liu, Ziyuan ^a   Tan, Xiaogang ^a   Zhou, Fang ^a   He, Max Y F ^a   Shao, Kang ^a   Li, Ning ^a   Qiu, Bin ^a   Sun, Jian ^a   Yu, Yue ^a   Wang, Suya ^a   Zhao, Yuda ^a   Shi, Xuejiao ^a   He, Jie ^a   more..

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; ISOCITRATE DEHYDROGENASE 1;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; KERATIN-19; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884548352     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0046     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Chen W, Zhang S, Zou X. [Estimation and projection of lung cancer incidence and mortality in China]. Zhongguo Fei Ai Za Zhi 2010;13:488-93.
4. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
5. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011;8:142-50.
6. Christenson RH. Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure. Clin Biochem 2008;41:208-9.
7. Salgia R, Harpole D, Herndon JE II, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 2001;21:1241-6.
8. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-18.
9. Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, Brown PR, et al. Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst 1988;80:97-101.
10. Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics 2012;11:M111.
11. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROSmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
12. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010;3:23-34.
13. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006;25:695-705.
14. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2000;2:811-20.
15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
16. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010;465:966.
17. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. WHO classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: International Agency for Research on Cancer; 2004.
18. Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turrisi III AT. Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC). Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
19. SB E, DR B, CC C, AG F, FL G, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
20. Li R, Wang Y. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi 1998;21:26-9.
21. Gu J, Wang X, Zhao H, Zhu S, Wen Y, Xu H, et al. [Diagnosis value of the detection of CYFRA21-1 in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:1118-21.
22. Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, et al. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis]. Sichuan Da Xue Xue Bao Yi Xue Ban 2008;39:832-5.
23. Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer 2013;132:2127-33.
24. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-74.
25. Mourtzikou A, Stamouli M, Kroupis C, Christodoulou S, Skondra M, Kastania A, et al. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics. Clin Lab 2012;58:441-8.
26. Lan YT, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al. Prognostic significance of perioperative change of CEA level in colorectal patients when pre-operative level is normal. Hepatogastroenterology 2012;59:717-20.
27. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-43.
28. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009;9:119.
29. Ma S, Shen L, Qian N, Chen K. The prognostic values of CA125, CA19.9, NSE, ANDSCCfor stage INSCLCare limited. Cancer Biomark 2011;10:155-62.
30. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCCin non-small cell lung cancer. Lung Cancer 1995;13:169-76.
31. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011;74:112-7.
32. Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejon D, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011;12:172-9.
33. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer 1994;30 A: 601-6.
34. Gounant V, Assouad J, Lavole A, Wislez M, Cadranel J, Milleron B. CT screening for lung cancer. Bull Cancer 2012;99:1039-44.
35. Dutt N, Hari DT. CT screening for lung cancer: so near, yet so far. Thorax 2012;67:651-2.
36. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
37. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007;13:249-55.